Literature DB >> 25499940

Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study.

Petter Bjornstad1, David M Maahs2, R Paul Wadwa3, Laura Pyle3, Marian Rewers3, Robert H Eckel4, Janet K Snell-Bergeon3.   

Abstract

BACKGROUND: Coronary artery disease and diabetic nephropathy, which are thought to share pathogenic mechanisms, remain the most common causes of mortality in type 1 diabetes (T1D). Data from basic and clinical studies indicate that hypertriglyceridemia plays an important role in the pathogenesis of vascular complications, but the role of triglycerides (TG) in the normal range remains unresolved in T1D.
OBJECTIVE: We hypothesized that fasting TG would independently predict cardiorenal disease in adults with T1D and normal-to-low levels of TG.
METHODS: Subjects (N = 652) were 19 to 56 years old at baseline and reexamined 6 years later. Urinary albumin excretion was measured, and categorized as microalbuminuria or greater. Progression of coronary artery calcification (CACp), measured using electron beam computed tomography, was defined as a change in the square root transformed CAC volume ≥2.5. The association of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein B, non-HDL-C, natural log triglyceride (lnTG), ln(TG/HDL-C) ratio with CACp and incident albuminuria were examined in logistic regression. The models were adjusted for age, sex, T1D duration, hemoglobin A1c, systolic blood pressure, diastolic blood pressure, blood pressure medications, statins, and smoking status. Integrated discrimination index and net reclassification improvement were used to examine prediction performance.
RESULTS: Incident albuminuria was independently associated with CACp. lnTG independently predicted both incident albuminuria (odds ratio: 1.53, 1.02-2.30, P = .04) and CACp (1.41, 1.11-1.80, P = .006). The addition of lnTG to ABC risk factors (HbA1c, systolic blood pressure, diastolic blood pressure, and LDL-C) moderately improved discrimination and reclassification of CACp and incident albuminuria.
CONCLUSION: In adults with T1D, fasting TG independently predicted cardiorenal disease over 6 years and improved reclassification of risk by conventional risk factors.
Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; Integrated discrimination index; Macrovascular complications; Microvascular complications; Net-reclassification improvement; Triglycerides; Type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 25499940      PMCID: PMC4268486          DOI: 10.1016/j.jacl.2014.08.008

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  17 in total

Review 1.  The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.

Authors:  Alicia Jenkins; Andrzej Januszewski; David O'Neal
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

Review 2.  Update on Estimation of Kidney Function in Diabetic Kidney Disease.

Authors:  Petter Bjornstad; David Z Cherney; David M Maahs
Journal:  Curr Diab Rep       Date:  2015-09       Impact factor: 4.810

Review 3.  Clinical imaging of vascular disease in chronic kidney disease.

Authors:  Alan A Sag; Adrian Covic; Gerard London; Marc Vervloet; David Goldsmith; Jose Luis Gorriz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2016-02-22       Impact factor: 2.370

4.  Effects of metreleptin on proteinuria in patients with lipodystrophy.

Authors:  Ho Lim Lee; Meryl A Waldman; Sungyoung Auh; James E Balow; Elaine K Cochran; Phillip Gorden; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2019-04-16       Impact factor: 5.958

5.  High Normal Urinary Albumin-Creatinine Ratio Is Associated With Hypertension, Type 2 Diabetes Mellitus, HTN With T2DM, Dyslipidemia, and Cardiovascular Diseases in the Chinese Population: A Report From the REACTION Study.

Authors:  Jie Wang; Yun Wang; Yijun Li; Ying Hu; Lingzi Jin; Weiqing Wang; Zhengnan Gao; Xulei Tang; Li Yan; Qin Wan; Zuojie Luo; Guijun Qin; Lulu Chen; Weijun Gu; Zhaohui Lyv; Yiming Mu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

6.  Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus.

Authors:  Petter Bjornstad; Robert H Eckel; Laura Pyle; Marian Rewers; David M Maahs; Janet K Snell-Bergeon
Journal:  Am J Cardiol       Date:  2015-07-16       Impact factor: 2.778

7.  Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study.

Authors:  Petter Bjornstad; Laura Pyle; David Z I Cherney; Richard J Johnson; Rachel Sippl; Randy Wong; Marian Rewers; Janet K Snell-Bergeon
Journal:  Nephrol Dial Transplant       Date:  2018-07-01       Impact factor: 5.992

8.  Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Authors:  Maritza J Romero; Rudolf Lucas; Huijuan Dou; Supriya Sridhar; Istvan Czikora; Eby M Mosieri; Ferenc G Rick; Norman L Block; Subbaramiah Sridhar; David Fulton; Neal L Weintraub; Zsolt Bagi; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

9.  Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes.

Authors:  Teresa Buckner; Baohai Shao; Robert H Eckel; Jay W Heinecke; Karin E Bornfeldt; Janet Snell-Bergeon
Journal:  J Clin Lipidol       Date:  2020-10-31       Impact factor: 5.365

10.  Relationship Between Dyslipidemia and Albuminuria in Hypertensive Adults: A Nationwide Population-Based Study.

Authors:  Sung-Ho Lee; Do Hoon Kim; Yang-Hyun Kim; Yong Kyun Roh; Sang Yhun Ju; Hyo-Yun Nam; Ga-Eun Nam; Jun-Seok Choi; Jong-Eun Lee; Jung-Eun Sang; Kyungdo Han; Yong-Gyu Park
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.